These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

658 related articles for article (PubMed ID: 19996015)

  • 1. Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization.
    Frelinger AL; Li Y; Linden MD; Barnard MR; Fox ML; Christie DJ; Furman MI; Michelson AD
    Circulation; 2009 Dec; 120(25):2586-96. PubMed ID: 19996015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypersensitivity of platelets to adenosine diphosphate in patients with stable cardiovascular disease predicts major adverse events despite antiplatelet therapy.
    Christie DJ; Kottke-Marchant K; Gorman RT
    Platelets; 2008 Mar; 19(2):104-10. PubMed ID: 17852773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance.
    Frelinger AL; Furman MI; Linden MD; Li Y; Fox ML; Barnard MR; Michelson AD
    Circulation; 2006 Jun; 113(25):2888-96. PubMed ID: 16785341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Usefulness of aspirin resistance after percutaneous coronary intervention for acute myocardial infarction in predicting one-year major adverse coronary events.
    Marcucci R; Paniccia R; Antonucci E; Gori AM; Fedi S; Giglioli C; Valente S; Prisco D; Abbate R; Gensini GF
    Am J Cardiol; 2006 Nov; 98(9):1156-9. PubMed ID: 17056317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study.
    Gurbel PA; Bliden KP; DiChiara J; Newcomer J; Weng W; Neerchal NK; Gesheff T; Chaganti SK; Etherington A; Tantry US
    Circulation; 2007 Jun; 115(25):3156-64. PubMed ID: 17562955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Letter by Violi et al regarding article, "Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization".
    Violi F; Pignatelli P; Basili S
    Circulation; 2010 Aug; 122(7):e429; author reply e430. PubMed ID: 20713906
    [No Abstract]   [Full Text] [Related]  

  • 7. Assessment of the antiplatelet effects of low to medium dose aspirin in the early and late phases after ischaemic stroke and TIA.
    McCabe DJ; Harrison P; Mackie IJ; Sidhu PS; Lawrie AS; Purdy G; Machin SJ; Brown MM
    Platelets; 2005 Aug; 16(5):269-80. PubMed ID: 16011977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Major clinical vascular events and aspirin-resistance status as determined by the PFA-100 method among patients with stable coronary artery disease: a prospective study.
    Christiaens L; Ragot S; Mergy J; Allal J; Macchi L
    Blood Coagul Fibrinolysis; 2008 Apr; 19(3):235-9. PubMed ID: 18388505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease.
    Lordkipanidzé M; Pharand C; Schampaert E; Turgeon J; Palisaitis DA; Diodati JG
    Eur Heart J; 2007 Jul; 28(14):1702-8. PubMed ID: 17569678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelet activation predicts recurrent ischemic events after percutaneous coronary angioplasty: a 6 months prospective study.
    Gianetti J; Parri MS; Sbrana S; Paoli F; Maffei S; Paradossi U; Berti S; Clerico A; Biagini A
    Thromb Res; 2006; 118(4):487-93. PubMed ID: 16343603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measuring aspirin resistance, clopidogrel responsiveness, and postprocedural markers of myonecrosis in patients undergoing percutaneous coronary intervention.
    Buch AN; Singh S; Roy P; Javaid A; Smith KA; George CE; Pichard AD; Satler LF; Kent KM; Suddath WO; Waksman R
    Am J Cardiol; 2007 Jun; 99(11):1518-22. PubMed ID: 17531573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistent platelet activation is related to very early cardiovascular events in patients with acute coronary syndromes.
    Małek ŁA; Spiewak M; Filipiak KJ; Grabowski M; Szpotańska M; Rosiak M; Główczyńska R; Imiela T; Huczek Z; Opolski G
    Kardiol Pol; 2007 Jan; 65(1):40-5; discussion 46. PubMed ID: 17295159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterogeneity in the suppression of platelet cyclooxygenase-1 activity by aspirin in coronary heart disease.
    Sciulli MG; Renda G; Capone ML; Tacconelli S; Ricciotti E; Manarini S; Evangelista V; Rebuzzi A; Patrignani P
    Clin Pharmacol Ther; 2006 Aug; 80(2):115-25. PubMed ID: 16890573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial.
    Serebruany VL; Malinin AI; Jerome SD; Lowry DR; Morgan AW; Sane DC; Tanguay JF; Steinhubl SR; O'connor CM
    Am Heart J; 2003 Oct; 146(4):713-20. PubMed ID: 14564328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors responsible for "aspirin resistance" - can we identify them?
    Postuła M; Tarchalska-Kryńska B; Filipiak KJ; Kosior D; Serafin A; Huczek Z; Opolski G
    Kardiol Pol; 2010 Apr; 68(4):403-11; discussion 412-3. PubMed ID: 20425699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relation between atherosclerosis risk factors and aspirin resistance in a primary prevention population.
    Faraday N; Becker DM; Yanek LR; Herrera-Galeano JE; Segal JB; Moy TF; Bray PF; Becker LC
    Am J Cardiol; 2006 Sep; 98(6):774-9. PubMed ID: 16950183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease.
    Würtz M; Grove EL; Kristensen SD; Hvas AM
    Heart; 2010 Mar; 96(5):368-71. PubMed ID: 19910291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical relevance of clopidogrel unresponsiveness during elective coronary stenting: experience with the point-of-care platelet function assay-100 C/ADP.
    Moerenhout CM; Claeys MJ; Haine S; Miljoen H; Bosmans JM; Vertessen F; Kluppels K; Van der Planken M; Vrints CJ
    Am Heart J; 2010 Mar; 159(3):434-8. PubMed ID: 20211306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up.
    Marcucci R; Gori AM; Paniccia R; Giusti B; Valente S; Giglioli C; Buonamici P; Antoniucci D; Abbate R; Gensini GF
    Circulation; 2009 Jan; 119(2):237-42. PubMed ID: 19118249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High on-treatment platelet reactivity by more than one agonist predicts 12-month follow-up cardiovascular death and non-fatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting.
    Marcucci R; Gori AM; Paniccia R; Giusti B; Valente S; Giglioli C; Buonamici P; Antoniucci D; Abbate R; Gensini GF
    Thromb Haemost; 2010 Aug; 104(2):279-86. PubMed ID: 20508896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.